Report Overview

The global antibiotics market size was valued at USD 35.7 billion in 2019 and is expected to expand at a compound annual growth rate (CAGR) of 4.5% from 20 to 2028.

The rising prevalence of infectious diseases and supportive government legislation are the major drivers of the market. Moreover, an increase in antibiotic resistance infections due to misuse or overuse of antibiotics is expected to shift the prescription patterns to novel therapies to treat bacterial infection. According to the CDC, the incidence of antibiotic-resistant infections is more than 2.8 million in the U.S. The pathogens such as Enterobacteriaceae, P. aeruginosa, and K. pneumoniae have a high resistance rate of an average of 40% in developed countries.



Market Drivers

Increasing number of patients suffering from infectious diseases drives the growth of antibiotics market. Ongoing clinical trials are being conducted by many pharmaceuticals companies will also boost up the antibiotics market growth. In addition, advances in antibiotics drugs and novel combination therapies to treat antibiotic-resistant microbial infections can advance the treatment landscape can also be a factor that drive the growth this market in the above forecasted period. Furthermore, a special designation from the regulatory authority to various potential pharmaceuticals companies is one of the factors which are expected to drive the market growth.

The rising threat of drug resistance and a weak pipeline of new molecules are leading to the development of combinational formulations. For instance, in countries, like India, the emergence of multi-drug-resistant tuberculosis (TB) is a major factor driving the R&D expenditures. Methicillin-resistant Staphylococcus aureus (MRSA) is another bacterium responsible for several infections in humans that are difficult to treat. The MRSA infection is difficult to treat with standard antibiotics, such as penicillins (methicillin, dicloxacillin, nafcillin, and oxacillin), and the cephalosporins. In 2014, the US Food and Drug Administration (FDA) approved four new antibiotics for the treatment of infections caused by gram-positive bacteria, including MRSA.